News

QRxPharma, a specialty pharmaceutical company, has successfully completed a Phase III program pilot study comparing the efficacy and safety profile of MoxDuo IR against component doses of morphine

Concurrent with the signing of the agreement, Bradley Somer will serve as Bio-Path’s medical officer and medical liaison for the conduct of the company’s upcoming Phase I clinical

BioAlliance Pharma said that plasmid AMEP displays anti-angiogenic and anti-metastatic properties. Results presented describe the anti-angiogenic and anti-tumoral properties of the plasmid AMEP biotherapy in in vitro and

Peregrine Pharmaceuticals, a biopharmaceutical company, has reported that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating bavituximab in combination with

PPD will provide clinical management services in key therapeutic areas from this new location in Japan. The office strengthens PPD’s operations in the country, where it has worked

Boston Scientific, a developer and marketer of medical devices, has reported a net loss of $13m, or $0.01 per diluted share, for the first quarter of 2009, compared

In this role, Mr Schaeffler will lead the organization’s public policy efforts in Washington, DC and report to DaVita CEO Kent Thiry. Prior to joining DaVita, Mr Schaeffler

The diagnostic test is based on technology being developed by Antigen Express. The technology being developed at Antigen Express allows for more potent and specific activation of immune

According to Wound Management Technologies, CellerateRx is FDA cleared as a medical device and is indicated for all acute and chronic wounds except for third degree burns. Cathy